Increased headcount should allow the FDA to up the number of approvals – but not quite yet.
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
The nightmare on the public markets is not confined to the bigger groups.
The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.